Omnicell, Inc. (NASDAQ:OMCL) Receives $57.86 Average PT from Analysts

Shares of Omnicell, Inc. (NASDAQ:OMCL) have earned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $57.8571.

A number of brokerages have recently issued reports on OMCL. Craig Hallum restated a “buy” rating and issued a $55.00 target price on shares of Omnicell in a research note on Wednesday, April 29th. Wall Street Zen upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 10th. Piper Sandler restated an “overweight” rating and issued a $45.00 price target (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd. Zacks Research downgraded Omnicell from a “hold” rating to a “strong sell” rating in a research report on Friday, August 7th. Finally, Wells Fargo & Company lowered their price target on Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, July 31st.

Hedge Funds Weigh In On Omnicell

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Dana Investment Advisors Inc. bought a new position in shares of Omnicell during the fourth quarter worth approximately $3,445,000. Universal Beteiligungs und Servicegesellschaft mbH lifted its holdings in shares of Omnicell by 71.1% during the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 140,032 shares of the company’s stock worth $6,343,000 after acquiring an additional 58,193 shares during the period. Teachers Retirement System of The State of Kentucky boosted its position in shares of Omnicell by 96.3% during the 4th quarter. Teachers Retirement System of The State of Kentucky now owns 25,914 shares of the company’s stock worth $1,174,000 after acquiring an additional 12,713 shares in the last quarter. Peregrine Capital Management LLC acquired a new stake in shares of Omnicell during the 4th quarter worth approximately $4,804,000. Finally, Bank of America Corp DE increased its stake in Omnicell by 31.3% in the first quarter. Bank of America Corp DE now owns 580,875 shares of the company’s stock valued at $19,390,000 after acquiring an additional 138,537 shares during the last quarter. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Omnicell Price Performance

Shares of NASDAQ OMCL opened at $35.58 on Friday. The stock has a market capitalization of $1.62 billion, a price-to-earnings ratio of 42.36, a PEG ratio of 0.89 and a beta of 0.98. Omnicell has a 12 month low of $29.06 and a 12 month high of $55.00. The firm’s 50 day simple moving average is $40.38 and its 200-day simple moving average is $39.61. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.64 and a quick ratio of 1.43.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.47. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The business had revenue of $312.21 million during the quarter, compared to the consensus estimate of $310.21 million. During the same period in the prior year, the company posted $0.45 EPS. The business’s quarterly revenue was up 7.4% on a year-over-year basis. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Analysts expect that Omnicell will post 1.41 EPS for the current year.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.